Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac
Heberprovac is a GnRH based vaccine candidate containing 2.4 mg of the GnRHm1-TT peptide as the main active principle; 245 μg of the very small size proteoliposomes adjuvant (VSSP); and 350 μL of Montanide ISA 51 VG oil adjuvant. The aim of this study was to assess the safety and tolerance of the He...
Similar Items
-
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
by: Venturelli M, et al.
Published: (2018-03-01) -
The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer
by: Günter Emons, et al.
Published: (2021-02-01) -
INTACT PROTEIN ABSORPTION BY THE FISH GUT. 2. APPLICATION POTENTIAL AND LIMITATIONS
by: Emin Teskeredžić, et al.
Published: (1998-10-01) -
Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer
by: Carsten Gründker, et al.
Published: (2021-02-01) -
Pengaruh Implantasi Hormon LHRH-A terhadap Perkembangan Gonad Kerapu Bebek, Cromileptes altivelis
by: Tridjoko Tridjoko
Published: (2006-02-01)